Q4 2021 Ph3BOM3 trial enrollment
Initial Cov19 ph2 data read-out
Q1 2022 Initiate Cov19 Ph3 trial
Q2 2022 Topline Ph2 data read-out for PAH
2H 2022 Ph3 data read-out Cov19
Q3 2022 Potential emergency use authorization EAU for Cov19
2023 BOMII Ph3 interim data read out for 300 targeted patients
2024 Potential BOM FDA Approval due to Breakthrough Therapy Designation